TOTAL: $64.88M | ||||
Year to Date: $108.68M | ||||
Company | Partner | Amt. | Triggering | Details (Date) |
Arena | Ortho-McNeil Inc. | $5 | Milestone payment | Triggered by Ortho-McNeil's initiation of a Phase I trial of the Type II diabetes candidate APD668 (2/7) |
Avant Immuno- | GlaxoSmithKline plc (UK) | $4 | Milestone payment | Triggered by European approval of Rotarix for the prevention of gastroenteritis caused by rotavirus; half the payment will go to Avant partners (2/27) |
BioDelivery | Clinical Development Capital LLC | $2 | Milestone payment | Triggered by BDSI's achievement of certain milestones in development of its BEMA Fentanyl formulation (2/16) |
Emisphere | F. Hoffmann- La Roche Ltd. (Switzerland) | ND | Milestone payment | Triggered by Roche's initiation of a clinical study using Emisphere's eligen delivery technology in a formulation for a second product (2/15) |
Genmab A/S | Serono SA (Switzerland; NYSE:SRA) | $1 | Milestone payment | Triggered by Genmab's delivery of a HuMax- TAC cell line to Serono, under their May 2005 agreement (2/27) |
Helix | Lumera Corp. (LMRA) | $0.125 | Milestone payment | Triggered by progress Lumera made in developing microarrays using technology from Helix (2/10) |
Isis | Eli Lilly and Co. | $0.75 | Milestone payment | Triggered by Lilly's initiation of a Phase I trial of the antisense cancer drug LY2275796 (2/1) |
Ligand | GlaxoSmithKline plc (UK) | $2 | Milestone payment | Triggered by GSK's start of Phase III trials of eltrombopag (SB497115), an oral platelet growth factor, in idiopathic thrombocytopenic purpura (2/14) |
MediGene AG | Astellas Pharma Inc. (Japan) | ND | Milestone payment | Triggered by the launch in France of a drug for treating advanced prostate cancer (2/17) |
Neose | Novo Nordisk A/S (Denmark) | ND | Milestone payment | Triggered by progress in deal to use Neose's GlycoPEGylation technology to develop a next-generation version of a protein marketed by Novo (2/9) |
New River | Shire plc (UK) | $50 | Milestone payment | The $50M payment followed the FDA's acceptance for review of New River's NDA for NRP104, a candidate for treating attention deficit hyperactivity disorder (2/7) |
Pharmacopeia | Celgene Corp. (CELG) | ND | Milestone payment | Triggered by delivery of compounds to Celgene under their drug discovery collaboration (2/8) |
7TM Pharma | Procter & Gamble Co. | ND | Milestone payment | Triggered by progress in the preclinical development of drugs for cardiovascular diseases under their January 2005 deal (2/22) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets; TSE = Toronto Stock Exchange. | ||||